{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:44Z","timestamp":1787026964122,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in almost 25-30% of androgen receptor (AR)-positive salivary gland carcinomas (SGCs), notably salivary duct carcinoma (SDC) and adenocarcinoma not otherwise specified (NOS). In the last years, several studies have reported the clinical benefit of HER2 directed therapies in this setting. This work aims at describing the natural history of AR-positive recurrent\/metastatic (R\/M) SGC patients, based on HER2 amplification status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive R\/M AR-positive SGC patients accessing our Institution from 2010 to 2021 were analyzed. Descriptive statistics and survival analyses were performed to present the clinical characteristics of the selected patients and the outcomes, based on HER2 status. A specific focus was dedicated to patients developing metastases to the central nervous system (CNS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-four R\/M AR-positive SGC patients (72 men) were analyzed. Median follow-up was 36.18 months (95% CI 30.19-42.66). HER2 status was available in 62 cases (84%) and in 42% the protein was overexpressed (HER2+). Compared with patients with HER2- SGCs, in patients with HER2+ disease, HR for disease recurrence was 2.97 (95% CI 1.44-6.1, p=0.003), and HR for death from R\/M disease was 3.22 (95% CI 1.39-7.49, p=0.007). Moreover, the HER2+ group showed a non-significant trend towards a higher prevalence of CNS metastases (40% vs. 24%, p=0.263). Patients developing CNS metastases had shorter survival than those who did not; at bivariate analysis (covariates: CNS disease and HER2 status), HER2 status demonstrated its independent prognostic significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In our patient population, HER2 amplification was a negative prognostic factor, and it was associated with a non-statistically significant higher risk of developing CNS metastasis. Further studies are needed to explore the potential clinical benefit of tackling the two biological pathways (AR and HER2) in patients affected by this rare and aggressive malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2022.1096068","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:29:40Z","timestamp":1673915380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["HER2 status in recurrent\/metastatic androgen receptor overexpressing salivary gland carcinoma patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Stefano","family":"Cavalieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imperia","family":"Nuzzolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Resteghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Quattrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Alessandro","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"B1","volume-title":"WHO classification of head and neck tumours","author":"El-Naggar","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1598376","article-title":"Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities","volume":"28","author":"Cavalieri","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.693394\/BIBTEX","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: A systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.55418\/9781933477947","volume-title":"AFIP atlas: tumors of the salivary glands (fifth series, vol. 5)","author":"Bishop","year":"2021"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck"},{"key":"B6","article-title":"Androgen Deprivation Therapy in Advanced Salivary Gland Cancer-ClinicalTrials.gov","year":""},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.28410","article-title":"Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy","volume":"15","author":"Locati","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_SUPPL.6018","article-title":"Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08\/KM11)","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":". J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDZ291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_SUPPL.6079","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies","volume":"39","author":"Bando","year":"2021","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: Clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.humpath.2019.08.009","article-title":"Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications","volume":"93","author":"Santana","year":"2019","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13122927","article-title":"Brain metastases in HER2-positive breast cancer: Current and novel treatment strategies","volume":"13","author":"Garcia-Alvarez","year":"2021","journal-title":"Cancers 2021 Vol 13 Page 2927"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12032-017-0919-0\/TABLES\/2","article-title":"Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review","volume":"34","author":"Ghidini","year":"2017","journal-title":"Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-016-2766-3\/FIGURES\/2","article-title":"Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study","volume":"16","author":"Hennigs","year":"2016","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.31353","article-title":"A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from the Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.33968","article-title":"Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified","volume":"128","author":"Sousa","year":"2022","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":":14584","DOI":"10.1038\/s41598-017-14607-2","article-title":"Targeting androgen receptor in treating HER2 positive breast cancer","volume":"7","author":"He","year":"2017","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/J.EJCA.2019.11.001","article-title":"Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort","volume":"125","author":"Pasquier","year":"2020","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","article-title":"Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm","volume":"66","author":"Alfieri","year":"2017","journal-title":"Oral Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2020.09.010\/ATTACHMENT\/A2F41A9B-15CE-4164-8FA7-8C2EFEC32D8B\/MMC1.PDF","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2019.00701\/FULL","article-title":"First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma\u2013a retrospective study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1096068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:29:43Z","timestamp":1673915383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1096068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":27,"alternative-id":["10.3389\/fonc.2022.1096068"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1096068","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"article-number":"1096068"}}